Cut costs by 97%? "Physical AI" enters biomanufacturing: Gao Te Jia leads Jin Du Sheng Ke's Series A round
New breakthroughs are emerging in the AI for Science space. Recently, Shenzhen Jindu Biomedical Technology Co., Ltd. (Jindu Bio) announced it has raised nearly 100 million RMB in its Series A funding round, led by Gotai Investment.
AI for Science is driving new breakthroughs.Recently, Shenzhen Jindu Biomedical Technology Co., Ltd. (hereinafter "Jindu Bio") announced the completion of its nearly 100 million yuan Series A financing round, led by GTJA Investment.。
Gao Te Jia Investment was founded in 2001 and has been deeply cultivated since 25.Healthcare, with assets under management exceeding 230 billion yuan, and having successively drivenBoyu Biological, Mindray Medical, United Imaging Healthcare, AkesoUntil 28 healthcare companies successfully go public. Teng Yuhang, Executive Partner of Gao Te Jia Investment, stated directly:
" AI is reshaping life sciences with global strategic investments. As a young yet highly innovative company, Jindu BioScience has built BioFord—a one-stop platform for biological research that transforms foundational life science into scalable, subscription-based "compute + lab" infrastructure. We are honored to lead this funding round and look forward to the company's continued breakthroughs in AI for BioScience.。"
This funding will be used forR&D of Physical AI Infrastructure, Iterative Upgrades to the BioFord Agent Platform, and Global Market ExpansionPrior to this, Jindu Shengke has secured multiple rounds of funding from investors including Sequoia Seed Fund, Chuang Dong Fang Investment, and Nanshan Strategic Emerging Industries Investment.
Dual-Engine Architecture: GeneLLM + BioFord
Jindu Shengke's core competitiveness lies in its dual-engine architecture.
GeneLLM — Multi-Omics Foundation Model, is the world's first multi-omics large model pre-trained on raw data. The current version features 15 billion parameters and has been pre-trained on a dataset of3.5 trillion base sequences, overwritetranscriptomics, genomics, epigenomics, metagenomics, proteomics, metabolomicsSix dimensions. The next version of the XLarge model is expected to achieve 300 billion parameters.
This is not a generic LLM wrapper. GeneLLM starts with raw, large-scale omics data, performs deep multi-dimensional understanding via unsupervised learning, then fine-tunes through supervised learning to deliver end-to-end disease representation correlation analysis. Performance is evaluated using multi-dimensional metrics including accuracy, sensitivity, specificity, and AUC.
BioFord Agent — Your One-Stop Embodied Autonomous Research PlatformThis large model has been embedded into a complete physical closed loop. The platform deploys a collaborative network of five intelligent agents: the literature retrieval agent for knowledge synthesis, the experimental design agent for generating protocols, the scientific reasoning agent for mechanistic modeling, the data analysis agent for attribution, and the experiment scheduling agent—controlling precise parameters such as liquid volume, temperature gradients, and time windows—to directly interface with and execute operations on physical equipment.
Connected hardware includesLeading pipetting workstations, incubators, centrifuges, and microplate readersReal-time tracking of the entire sample lifecycle, fully recorded on-chain. 7×24-hour experiments run without interruption, with continuous comparison and automatic calibration between predicted and measured values—truly achievingDesign → Build → Test → LearnClosed loop.
Biomanufacturing: 83x throughput increase, 97% cost reduction
The data Jindu Shengke has delivered in the field of biomanufacturing is worth a closer look.
Increased throughput for E. coli vector construction83xImproved efficiency in protein expression detection5.6xImproved tag protein purification efficiency6.7xsgRNA library for AI-assisted gene editing design, with costs lower than similar imported reagents97%achieve domestic substitution.
This is not a proof-of-concept from the lab; it's a product capability already being delivered to 30+ leading institutions. Jindu Shengke's client list includesBGI, PUMC Cancer Center, Shanghai East Hospital, Chinese Academy of Environmental SciencesMeanwhile, the proportion of overseas business continues to rise. They have also partnered with Baidu Intelligent Cloud to launch the world's first AI4S-native closed-loop life sciences laboratory at a leading Chinese university.
From basic research to medical diagnostics (Alzheimer's disease 5-year risk prediction with an AUC of 0.91, preterm birth prediction in pregnant women with an AUC of 0.89), to biomanufacturing and bio-breeding, the application areas covered by Jindu Bio are exactly2026 (2nd) Yimao Bio-Manufacturing Industry Conference & Exhibition (SummerFocus industries.
2026 (2nd) EMBC Bio-Manufacturing Industry Conference & Exhibition (Summer)
Where AI meets biomanufacturing: the most precise connection point.Jindu Shengke has confirmed its participation in the 2026 (2nd) Yimao Bio-manufacturing Industry Conference & Exhibition (Summer).。
The exhibition will be8 27-28Held in Shanghai, the exhibition will invite2000+ Attendees,100+Speaker,20+Premium exhibitors, featuring "Exhibitions - Conferences - Meetings - EventsFour core modules focused on "breakthroughs in fundamental research + cross-domain industrial implementation."
Exhibition FocusMedical Aesthetics, Bio-based Materials & Green Chemicals, Food, Agriculture, and AI EmpowermentExhibitor recruitment is now open. Contact us for details on participating in the exhibition.
